Pterospermum

Pterospermum: Botanical Identity, Phytochemistry, Traditional Use, and Scientific Evidence

1. Identity and Botanical Classification

Pterospermum is a genus of flowering trees placed, in current systematics, in the family Malvaceae (order Malvales). It is a genus of flowering plants in the mallow family Malvaceae, comprising tropical trees that range from southern China across tropical Asia. Traditionally included in the family Sterculiaceae, it has been incorporated into the expanded Malvaceae in the APG classification and most subsequent systematic treatments. The genus name derives from the Greek: "Pteron" and "Sperma," meaning "winged seed," a direct reference to the winged seeds characteristic of the genus.

The genus was formally published by Schreb. (1791), recorded in Gen. 461. The most pharmacologically studied species is Pterospermum acerifolium (L.) Willd., which was described by Willdenow and published in Sp. Pl. 3: 729 (1802), belonging to the kingdom Plantae, phylum Tracheophyta, class Magnoliopsida, order Malvales, family Malvaceae. Its species epithet, acerifolium, indicates maple-shaped leaves. Accepted synonyms include Cavanilla acerifolia (L.) J.F.Gmel., Dombeya acerifolia (L.) Gaertn., Pentapetes acerifolia L., and Pterospermadendron acerifolium (L.) Kuntze.

Other medically or botanically notable species within the genus include Pterospermum heterophyllum, Pterospermum lanceifolium, Pterospermum javanicum, Pterospermum semisagittatum, Pterospermum subpeltatum, Pterospermum heyneanum, Pterospermum truncatolobatum, and Pterospermum menglunense (an endangered species endemic to Yunnan Province, China). Some species are grown ornamentally while others are valued for their timber.

1.1 Common Names

P. acerifolium is commonly known as the Bayur Tree and the Dinner-plate tree, and in Hindi as Kanakchampa or Muchukunda. Additional Sanskrit names documented in Ayurvedic literature include Muchkunda, Pushp, Parivyadh, and Karnikar. In classical Ayurvedic texts it is referred to as Kanak Champa / Muchkunda. In Myanmar, the plant is known by the names magwinapa, sinna, taung-petwun, and taw-kalamet. The common name "dinner plate tree" is explained by the leaves: mature leaves are very large, reaching up to thirty-five centimeters in length and width, and can be used as dinner plates or for packaging and storage; in India they are shaped into regular dinner plates and soup bowls on moulds, some even stitched together with twigs.

1.2 Morphology and Geographic Distribution

The plant is a large tree, up to 30 m tall, with grey bark and rusty pubescent young parts. Leaves are oblong, broadly obovate to ovate, orbicular or rectangular, 10–40 cm long, 8–35 cm broad, cordate, often peltate; silvery to rusty pubescent beneath and dark green above. Flowers are mostly solitary, 10–15 cm long and across, white and fragrant. The tree is found in the sub-Himalayan tract and outer Himalayan valleys and hills up to 4,000 ft., Bengal, Chittagong, Khasia Hills, Manipur, Darjeeling, and Odisha, and has been extensively planted in the Bombay State.

1.3 Dosage Forms and Preparations

The plant belongs to the family Malvaceae and is valued for its flowers, bark, leaves, and roots, which possess significant therapeutic properties. Parts used medicinally include the bark, flowers, leaves, roots, fruits, and seeds. Traditional preparations include flowers used in cooling decoctions and infusions; bark used in Kwatha (decoction) for Prameha (diabetes) and Jwara (fever); and leaf paste applied externally in inflammation and burning sensation. In scientific research, extracts have been prepared using ethanol, methanol, aqueous, hexane, acetone, and ethyl acetate solvents from various plant parts. Bark extracts, flower extracts, and isolated fractions have all been employed in preclinical studies.

---

2. Traditional and Historical Use

2.1 Ayurvedic Tradition (India)

The plant is an important medicinal plant widely described in classical Ayurvedic literature and traditionally used in various parts of India. In Ayurveda, Muchkunda is attributed with Tikta and Kashaya Rasa, Sheeta Virya, and Kapha-Pitta Shamaka action. It is indicated in conditions such as Daha (burning sensation), Trishna (excessive thirst), Jwara (fever), Raktapitta (bleeding disorders), Prameha (diabetes syndrome), Kasa (cough), and inflammatory disorders. Classical texts highlight its role as a Vedanasthapaka (analgesic), Dahaprashamana (relieves burning sensation), and Vranaropaka (wound-healing) drug.

In traditional medicine, different parts of the tree in various dosage forms have been used to treat many diseases for thousands of years, mainly for ear ache, small pox, leucorrhoea, inflammation, ulcers, leprosy, and diabetes syndrome. Traditionally the plant has also been used as a general tonic, anti-tumor agent, analgesic, and for the treatment of gastrointestinal disorders, blood troubles, bronchitis, cough, cephalic pain, migraine, and as a haemostatic and antimicrobial agent.

2.2 Folk and Tribal Use

In India the plant is considered antiseptic, depurative, and tonic; also employed for eruptions, fever, inflammation, leprosy, menorrhagia, puerperium, smallpox, sores, and tumors. Hill people use the white tomentum from the under surface of the bark to stop bleeding; flowers are used as a general tonic; and flowers and bark charred and mixed with kamala are applied in suppurating smallpox. Flowers made into paste with rice water are used as an application for hemicrania (one-sided headache). The flowers of Pterospermum acerifolium are commonly consumed by the tribal folks of the Chota Nagpur region of Jharkhand, India.

Flowers are reported to be used as tonic, anthelmintic, anti-inflammatory, laxative, and to cure abdominal pain, ascites, ulcers, leprosy, urinary discharges, and tumors. Flowers and bark are charred, mixed with kamala, and applied in suppurating small-pox.

2.3 Traditional Use in Southeast Asia

In Malaysia, Pterospermum is distributed in the states of Peninsular Malaysia, Sarawak, and Sabah. For centuries, the Bidayuh tribe in Sarawak has been using an indigenous plant called Bayur to cure patients diagnosed with breast cancer. In South China a tincture of the root of Pterospermum heterophyllum is drunk to treat rheumatism and ostealgia. For P. heterophyllum, the roots of the plant are commonly used in traditional medicine to treat rheumatoid arthritis. Species of the Pterospermum genus have been traditionally used across the region to cure inflammation, blood troubles, leprosy, tumors, hemostasis, ear pain, stomachache, smallpox, leucorrhoea, and ulcers.

---

3. Key Chemical Constituents

Phytochemical investigations unveil various compounds, including phytoceramides, acylated phytosterol glucosides, flavones, flavonoids, triterpenoids, phenolic compounds, and glycosides. Phytochemical investigations also reveal the presence of tannins and sterols, which contribute to its wide spectrum of biological actions.

3.1 Triterpenes and Sterols

Many triterpenes and flavonoids have been isolated from the different organs of P. acerifolium. Leaves and bark were found to contain taraxerol, friedelin, friedelin-3-one, β-sitosterol, and β-sitosterol glucoside. Flavonoids like kaempferol, kaempferide, luteolin, steroids, and triterpenoids like sitosterol, taraxerol, and friedelin, along with sugars and fatty acids, are present in the plant. Three phenolic acid derivatives were isolated for the first time from the genus Pterospermum from the chloroform and ethyl acetate fractions of the ethanolic extract of the fruits: methyl protocatechuate, vanillic acid, and protocatechuic acid, in addition to β-sitosterol-3-O-β-D-glucoside.

Lupeol is another notable triterpenoid isolated from P. acerifolium, particularly from the flowers. The lipid-lowering effect of lupeol isolated from the hydro-alcoholic extract of the flower of P. acerifolium was evaluated in triton- and diet-induced hyperlipidemic models. The extract (at 400 mg/kg dose level) and lupeol (at 20, 40, and 80 mg/kg dose levels) inhibited the elevation in serum cholesterol and triglyceride levels.

Taraxerol has been isolated from the leaves and studied for cytotoxic activity. Cytotoxic activity of taraxerol isolated from the leaves of Pterospermum acerifolium and its EtOH extract was evaluated against human breast, colon, and lung cancer cell lines.

3.2 Flavonoids

HPLC analysis of the bioactive subfraction PAFE2 (from flowers) reveals the presence of quercetin and apigenin as major constituents, and both are inhibiting the glycogen phosphorylase enzyme in molecular modelling studies. A novel luteolin analogue and a kaempferol analogue isolated from the flower of P. acerifolium possessed osteogenic effects by stimulating osteoblast differentiation.

3.3 Phenolic Acids

Bark extracts of P. acerifolium are a rich source of bioactive constituents including phenolic compounds (2.36%), alkaloids (2.10%), flavonoids (1.84%), and tannin (2.16%) per dry weight.

3.4 Other Species

In P. heyneanum (stem), terpenoids including cyclopterospermol, 30-norcyclopterospermol, and 30-norcyclopterospermone have been identified, along with miscellaneous compounds such as n-octacosanol and 3-hydroxy-5-methoxy-2-methylbenzoquinone. Betulonic acid in Pterospermum truncatolobatum inhibits cancer in the cell lines KB (epidermoid carcinoma), LU (lung carcinoma), MCF-7 (breast carcinoma), and HepG2 (liver carcinoma). The phytoconstituents present in the methanolic extract of leaf petioles include tannins, saponins, steroids, terpenoids, coumarins, and betacyanins, while the aqueous extract contains tannins, glycosides, reducing sugars, saponins, steroids, terpenoids, coumarins, and betacyanins.

---

4. Pharmacology and Scientific Evidence by Area

The overwhelming majority of existing research on Pterospermum consists of in vitro (cell-based) and in vivo (animal model) preclinical studies. No robust human clinical trials have been published in the peer-reviewed literature for any indication. All evidence described below must be interpreted in that context.

4.1 Anti-Inflammatory and Analgesic Activity

Evidence level: Preclinical only (in vitro and animal models).

Modern pharmacological studies have demonstrated anti-inflammatory and analgesic activities of Pterospermum acerifolium. The alcoholic extract of P. acerifolium fruits showed significant anti-inflammatory activity in a preclinical study, reaching 61% of indomethacin potency at a dose of 100 mg/kg body weight. The ethyl acetate fraction of P. acerifolium showed the highest free radical scavenging activity in various in vitro antioxidant assays, and this fraction also demonstrated significant anti-inflammatory effects in both in vivo and in vitro models of inflammation, supporting the traditional use of P. acerifolium for reducing oxidative stress and inflammation.

Leaves of P. acerifolium are used in India for reducing oxidative stress and inflammation. An investigation of these activities used in vitro antioxidant models including total phenolic determination, DPPH radical scavenging, nitric oxide scavenging, hydroxy radical scavenging, and superoxide anion scavenging assays. Anti-inflammatory activity was evaluated using carrageenan-induced inflammation and thermally induced protein denaturation. The ethyl acetate fraction showed the highest free radical scavenging activity in all models. No human clinical data are available.

4.2 Antioxidant Activity

Evidence level: In vitro only.

Antioxidant evaluation of bark extracts showed that the acetone extract is high in total phenol, total ascorbic content, and total antioxidant content, whereas DPPH free radical scavenging, ABTS, and metal chelating activity assays were higher in the ethanol extract, compared to the standard antioxidant BHT. Crude extracts assessed for antioxidant potential showed promising anti-radical activity at 100 ppm concentration. These findings are purely from cell-free in vitro systems and cannot be extrapolated to clinical effects without further study.

4.3 Antidiabetic / Antihyperglycemic Activity

Evidence level: In vitro and animal models only; no human data.

A published study designed to estimate the detailed antidiabetic activity of Pterospermum acerifolium (L.) Willd. flowers performed an in vitro alpha-amylase inhibition study on a 50% ethanol extract of flowers (PAFEE) and its various fractions. The active ethyl acetate fraction (PAFEF) was subfractionated into three subfractions (PAFE1, PAFE2, PAFE3) and subjected to acute toxicity studies followed by antidiabetic screening in vivo by streptozotocin-nicotinamide-induced type II diabetes. Diabetic animals treated with PAFE2 at 30 mg/kg showed significantly reduced fasting blood glucose (P < 0.001) compared to diabetic control animals. Histological studies on drug-treated groups did not show remarkable positive changes in β-cells. PAFE2 showed 32.6 ± 1.93% glucose uptake over control, and in the presence of PI3K inhibitor wortmannin, this declined to 13.7 ± 2.51%. HPLC analysis of PAFE2 revealed quercetin and apigenin as major constituents, both inhibiting glycogen phosphorylase in molecular modelling studies. The study evidenced that the probable glucose-lowering mechanism of action is by increasing glucose uptake in peripheral tissues and by inhibition of gluconeogenesis.

Additionally, Pterospermum acerifolium bark was traditionally used for the treatment of diabetes mellitus, and the in silico antidiabetic activity of β-sitosterol — isolated as a major phytoconstituent from the bark — was determined, with molecular modeling results revealing β-sitosterol as a potential inhibitor of human pancreatic alpha-amylase (HPA) in comparison with acarbose. Chronic effects of P. acerifolium on glycemic and lipidemic status in type 2 model diabetic rats were found beneficial. All of this evidence is from animal and computational models; human clinical trials have not been conducted.

4.4 Antimicrobial Activity

Evidence level: In vitro only.

Bark and flower extracts are used in traditional medicine because of their antibacterial and antifungal activity. Crude extracts of P. acerifolium demonstrate good antifungal and antibacterial effects in vitro. For the related species P. heterophyllum, extracts from the leaves and stems revealed the ability to resist all three bacterial strains tested (Escherichia coli, Pseudomonas aeruginosa, and Streptococcus aureus), and P. heterophyllum also inhibited the growth of three fungal strains: Aspergillus brasiliensis, Candida albicans, and Aspergillus flavus. All antimicrobial results derive from laboratory-based in vitro assays.

4.5 Anticancer / Cytotoxic Activity

Evidence level: In vitro (cell lines) only; no human clinical data.

Pterospermum acerifolium has a broad application in the traditional Indian medicinal system including cancer treatment, but no study was previously available on the cytotoxic and apoptotic effect of P. acerifolium in human cancer cells. Researchers decided to demonstrate the anti-carcinogenic property of P. acerifolium ethanolic bark extract against lung (A549) and pancreatic (PANC-1) cancer cells. Fluorescence microscopic studies using acridine orange/ethidium bromide and DAPI staining showed early and late apoptotic symptoms. Rhodamine-123 and DCFH-DA staining analysis by flow cytometry showed that bark extract depolarized the mitochondrial membrane potential and induced reactive oxygen species (ROS) generation. Cell cycle analysis showed that P. acerifolium bark extract arrested A549 and PANC-1 cells in sub-G1 phase, indicating early apoptosis. These findings collectively demonstrate that P. acerifolium bark extract induced cell cytotoxicity in lung and pancreatic cancer cells by modulating mitochondrial-mediated ROS generation and cell cycle checkpoints.

For taraxerol isolated from the leaves: the extract and isolated compound were analyzed for cytotoxic activity on MDA-MB-231, BT-549, A-549, and SW-480 cancer cell lines by MTT assay. The extract and isolated compound taraxerol both displayed excellent inhibitory activity (IC50: 80 µg/mL for extract and 160 µg/mL for compound) on breast cancer cell line MDA-MB-231.

For P. heterophyllum, evaluation of anticancer activity showed that extracts significantly reduced the proliferation of HepG2 liver cancer cells, with IC50 values for leaf and stem extracts being 35.5 and 47.17 µg/mL, respectively, and the extract also inhibited the migration ability of HepG2 cells after 24 hours of treatment.

In Malaysia, UHPLC-QQQ/MS analysis of bark extract from an indigenous Pterospermum species showed the presence of anti-cancer agents, supporting the potential of the indigenous plant for breast cancer treatment.

All cancer-related findings are in vitro and cannot be used to infer clinical efficacy in humans.

4.6 Hepatoprotective Activity

Evidence level: Preclinical (animal) only.

The hepatoprotective effect of an ethanolic extract of the leaves of P. acerifolium has been reported in experimental studies. This effect aligns with the Ayurvedic attribution of the plant as a Hrudya (cardiotonic/protective) herb, but no human study has confirmed hepatoprotective outcomes.

4.7 Wound Healing Activity

Evidence level: Animal model only.

Wound healing activity of ethanolic extract of P. acerifolium flower, along with its effect on tumor necrosis factor-α (TNF-α), was assessed using an excision model of wound repair in Wistar albino rats. The antioxidant property of P. acerifolium and the presence of flavonoids, which scavenge free radicals, help in the healing of wounds. The study concluded that P. acerifolium has a good wound healing potential, and that the accelerated healing process and induction of TNF-α may be the mechanisms involved in wound healing.

4.8 Antihyperlipidemic Activity

Evidence level: Animal model only.

Lipid-lowering effects of lupeol isolated from the hydro-alcoholic extract of the flower of P. acerifolium were evaluated in triton- and diet-induced hyperlipidemic models in Wistar albino rats. The extract (at 400 mg/kg dose level) and lupeol (at 20, 40, and 80 mg/kg dose levels) inhibited the elevation in serum cholesterol and triglyceride levels. No human evidence is available.

4.9 Anthelmintic Activity

Evidence level: In vitro and preliminary animal models.

The flowers are described as anthelmintic in Ayurvedic tradition. Barks are used as anthelmintic in treating animals. A scientific study on crude extracts and fractions of different parts of P. acerifolium confirmed anthelmintic potential against laboratory worm models. No clinical evidence is available.

4.10 Immunomodulatory / Immunosuppressive Activity

Evidence level: Animal model only.

Hexane and ethanolic extracts prepared from the seeds of P. acerifolium were evaluated for immunomodulatory activities by studying their effects on the humoral and cellular immune arms of BALB/c mice after oral administration for 14 consecutive days at different log doses. Immune parameters including lymphoproliferative index, oxidative burst in peritoneal macrophages, modulation in T/B cell population, and regulation of Th1/Th2 cytokines were monitored. Both extracts exerted remarkable dose-dependent immunosuppressive effects with down-regulation of all the immune markers studied.

4.11 Osteogenic Activity

Evidence level: In vitro only.

A novel luteolin analogue and a kaempferol analogue isolated from the flower of P. acerifolium possessed osteogenic effects by stimulating osteoblast differentiation in vitro. These findings are purely from cell-based assays.

4.12 Antiulcer Activity

Evidence level: Animal model only.

The barks are reported to be used as anti-ulcer in traditional medicine, and preclinical studies support anti-inflammatory, analgesic, and anti-oxidant activity for these applications. Bark extract has been studied for effects on oxidative damage in gastric tissue during alcohol-induced ulceration in animal models.

---

5. Body Systems and Health Areas

• Metabolic / Endocrine: Antihyperglycemic and antihyperlipidemic effects observed in animal models; mechanisms include alpha-amylase inhibition, PI3K-mediated glucose uptake, and gluconeogenesis inhibition.
• Immune System: Immunosuppressive effects demonstrated in BALB/c mice studies; potential relevance in autoimmune and inflammatory contexts.
• Gastrointestinal: Antiulcer activity in animal models; traditional use for abdominal pain, ascites, and digestive complaints.
• Musculoskeletal / Skeletal: Osteogenic (bone-forming) activity demonstrated in cell assays via luteolin and kaempferol analogues.
• Oncology (Preclinical): Cytotoxic activity against lung, pancreatic, breast, colon, and liver cancer cell lines; mechanisms involve mitochondrial ROS generation, cell cycle arrest, and apoptosis induction.
• Dermatological / Wound Healing: Wound healing demonstrated in excision models; traditional uses include skin diseases, smallpox, and leprosy.
• Cardiovascular / Lipid: Antihyperlipidemic activity via lupeol in animal models.
• Hepatic: Hepatoprotective effects from leaf extracts in animal studies.
• Antimicrobial: Activity against multiple bacterial and fungal species in in vitro assays.

---

6. Dosages Reported in Preclinical Studies

The following dosages appear specifically in published preclinical studies and are not established human clinical doses.

• Diabetic animals treated with PAFE2 at 30 mg/kg showed significantly reduced fasting blood glucose (P < 0.001).
• In hyperlipidemic models, the flower extract was tested at 400 mg/kg, and isolated lupeol at 20, 40, and 80 mg/kg dose levels.
• The alcoholic extract of fruits showing anti-inflammatory activity was tested at 100 mg/kg body weight.
• Immunosuppressive effects were studied at 3, 10, and 30 mg/kg doses in BALB/c mice after oral administration for 14 consecutive days.
• In cancer cell cytotoxicity studies, A549 (lung) cells were treated with bark extract at 50 and 100 µg/mL, and PANC-1 (pancreatic) cells at 50 and 75 µg/mL.
• Taraxerol from leaves demonstrated an IC50 of 160 µg/mL against MDA-MB-231 breast cancer cells; the crude EtOH extract had an IC50 of 80 µg/mL.
• Leaf and stem extracts of P. heterophyllum exhibited IC50 values of 35.5 and 47.17 µg/mL, respectively, against HepG2 liver cancer cells.
• For acute oral toxicity studies conducted on OECD guidelines 423, 2000 mg/kg was fixed as the initial dose for ethyl acetate fraction, and 300 mg/kg for subfractions.

---

7. Safety Considerations

7.1 Acute Toxicity (Preclinical)

The alcoholic and aqueous extracts of P. acerifolium fruits were found to be safe with an LD50 of 7.6 and 7.9 g/kg body weight, respectively, in animal safety studies. For the ethyl acetate fraction of P. lanceifolium leaf, the LD50 was found to be greater than 2000 mg/kg. The sub-acute study demonstrated that doses of 200 and 400 mg/kg did not impart any significant change in any measured parameter. Acute dermal toxicity analysis indicated no mortality in rats and no significant change in biochemical parameters when exposed to 1% and 5% concentrations.

Acute and subchronic toxicity studies of hydroalcoholic flower extract of P. acerifolium in albino mice and rats assessed parameters including food and fluid intake, body weight, organ weights (lung, liver, pancreas, kidney, heart, and spleen), haematological parameters, and liver function tests including SGOT, SGPT, alkaline phosphatase, and total bilirubin, at doses of 1000, 2000, and 4000 mg/kg orally.

7.2 Immunosuppressive Properties: A Critical Safety Note

Seed extracts of P. acerifolium (hexane and ethanolic) exerted dose-dependent immunosuppressive effects with down-regulation of all immune markers studied, including lymphoproliferative index, oxidative burst in peritoneal macrophages, T/B cell populations, and Th1/Th2 cytokines, after oral administration for 14 consecutive days at 3, 10, and 30 mg/kg in BALB/c mice. This immunosuppressive effect, documented in animal models, is a pharmacologically relevant property that would warrant particular caution in individuals with compromised immunity or those using immunosuppressive medications, if the plant were to be consumed.

7.3 Absence of Human Clinical Safety Data

There are no published human clinical trials evaluating the safety, tolerability, or pharmacokinetics of any Pterospermum preparation. All safety data derive from animal (rodent) toxicology studies. The immunosuppressive activity documented in animal research, combined with the absence of human data, means that safety in human populations remains unknown. No established safe dose range has been defined for humans, and no regulatory agency (NIH, EMA, WHO, ESCOP, or others) has published a monograph or formal safety evaluation for any Pterospermum preparation as of the time of writing.

7.4 Potential Interactions

Based on the pharmacological evidence from preclinical studies, the following interactions are biologically plausible, though not established in human studies:

• Potential additive or synergistic effects with antidiabetic medications (alpha-glucosidase inhibitors, insulin sensitizers), given demonstrated in vivo hypoglycemic activity.
• Potential interaction with immunosuppressive drugs (cyclosporine, tacrolimus, corticosteroids), given the documented immunosuppressive activity of seed extracts in animals.
• Potential additive effects with lipid-lowering agents (statins, fibrates), given the antihyperlipidemic activity of lupeol demonstrated in rodent models.

---

8. Summary of Evidence Strength

The plant's pharmacological activities span antioxidant, anti-inflammatory, antimicrobial, anticancer, analgesic, antihyperglycemic, antihyperlipidemic, antinociceptive, antiulcer, hepatoprotective, immunosuppressive, and wound healing effects, supported by various studies. However, the available research stresses the importance of further scientific evaluation for a deeper understanding of its therapeutic potential. The entire body of scientific research on Pterospermum consists of preclinical studies — primarily in vitro cell culture assays and in vivo rodent models. No randomized controlled trials, prospective cohort studies, or other forms of human clinical evidence exist for any Pterospermum species or preparation. The evidence base is best characterized as preliminary and hypothesis-generating. The richness of traditional use across multiple Asian cultures provides ethnopharmacological credibility that justifies ongoing scientific investigation, but it does not substitute for clinical evidence of efficacy or safety in humans.

References

• Wikipedia – Pterospermum (genus)
• Wikipedia – Pterospermum acerifolium
• GBIF – Pterospermum acerifolium (L.) Willd.
• GBIF – Pterospermum Schreb. (Genus)
• Plants of the World Online (Kew) – Pterospermum acerifolium
• World Flora Online – Pterospermum acerifolium (L.) Willd.
• PMC – Complete chloroplast genome of Pterospermum menglunense (2021)
• PMC / PubMed – Antidiabetic Activity of Pterospermum acerifolium Flowers (2014)
• PubMed – P. acerifolium bark extract induces anticarcinogenic effect via mitochondrial ROS (2018)
• ScienceDirect – Cytotoxicity of taraxerol from P. acerifolium leaves (2020)
• Tandfonline – Anticancer agents and genetic identification of Pterospermum, Sarawak (2024)
• De Gruyter – Antimicrobial activity and ROS generation in HepG2 cells: P. heterophyllum (2024)
• European Journal of Medicinal Plants – Insights into Pterospermum acerifolium (Vijay et al., 2023)
• Journal of Pharmacognosy and Phytochemistry – Comprehensive review of Pterospermum acerifolium (2026)
• Journal of Pharmacognosy and Phytochemistry – P. acerifolium: Ethnomedicinal uses, phytochemistry, pharmacology (2023)
• ResearchGate – Insights into Pterospermum acerifolium: A Rare Gem of Central Indian Flora (2024)
• ResearchGate – Contemporary Literary Review of Muchakunda (Pterospermum acerifolium) (2021)
• ResearchGate – Phytochemical and Biological Investigations of Pterospermum acerifolium Wild Bark (Muhit et al., 2010)
• ResearchGate – Phytochemical and Pharmacological Study of P. acerifolium Growing in Egypt (2006)
• ResearchGate – Immunosuppressive activity of P. acerifolium seeds in BALB/c mice (Pathak et al., 2011)
• Journal of Basic and Clinical Pharmacy – Wound healing potential of P. acerifolium with induction of TNF-α (2011)
• Global Research Online – Anthelmintic potential of P. acerifolium crude extracts
• Journal of Community Health Research – Oral and dermal toxicity profiling of ethyl acetate fraction of P. lanceifolium leaf
• Academia.edu – Antioxidant, antimicrobial activity and phytochemical investigation of P. acerifolium leaf petiole
• Academia.edu – In vitro antimicrobial and antioxidant activity of P. acerifolium leaves
• Academia.edu – Toxicological Studies of the Hydroalcoholic Extract of P. acerifolium Flowers
• International Journal of Pharmaceutical Chemistry – Phytochemical analysis and antioxidant activity of P. acerifolium (2016)